Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543596

2023-01-01

Abstract:<p>All Supplementary Figures (1-9)</p>

What problem does this paper attempt to address?

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Xin Lin,Zaozao Zheng,Junyi Liu,Yujie Chen,Junqiang Ding,Guosheng Hu,Yahong Hu,Suling Liu,Wenxin Luo,Ningshao Xia,Wen Li

DOI: https://doi.org/10.1158/2326-6066.22543596.v1

2023-01-01

Abstract:All Supplementary Figures (1-9)
Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543587

2023-01-01

Abstract:<p>Supplementary Table 2</p>
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.cir-20-0405

IF: 10.1

2021-04-19

Cancer Immunology Research

Abstract:Abstract EGFR-targeted chimeric antigen receptor (CAR) T cells are potent and specific in suppressing the growth of triple-negative breast cancer (TNBC) in vitro and in vivo. However, in this study, a subset of mice soon acquired resistance, which limits the potential use of EGFR CAR T cells. We aimed to find a way to overcome the observed resistance. Transcriptomic analysis results revealed that EGFR CAR T-cell treatment induced a set of immunosuppressive genes, presumably through IFNγ signaling, in EGFR CAR T-cell–resistant TNBC tumors. The EGFR CAR T-cell–induced immunosuppressive genes were associated with EGFR CAR T-cell–activated enhancers and were especially sensitive to THZ1, a CDK7 inhibitor we screened out of a panel of small molecules targeting epigenetic modulators. Accordingly, combination therapy with THZ1 and EGFR CAR T cells suppressed immune resistance, tumor growth, and metastasis in TNBC tumor models, including human MDA-MB-231 cell–derived and TNBC patient–derived xenografts, and mouse EMT6 cell–derived allografts. Taken together, we demonstrated that transcriptional modulation using epigenetic inhibitors could overcome CAR T-cell therapy–induced immune resistance, thus providing a therapeutic avenue for treating TNBC in the clinic.

oncology,immunology
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Meenakshi Anurag,Eric J. Jaehnig,Karsten Krug,Jonathan T. Lei,Erik J. Bergstrom,Beom-Jun Kim,Tanmayi D. Vashist,Anh Minh Tran Huynh,Yongchao Dou,Xuxu Gou,Chen Huang,Zhiao Shi,Bo Wen,Viktoriya Korchina,Richard A. Gibbs,Donna M. Muzny,Harshavardhan Doddapaneni,Lacey E. Dobrolecki,Henry Rodriguez,Ana I. Robles,Tara Hiltke,Michael T. Lewis,Julie R. Nangia,Maryam Nemati Shafaee,Shunqiang Li,Ian S. Hagemann,Jeremy Hoog,Bora Lim,C. Kent Osborne,D.R. Mani,Michael A. Gillette,Bing Zhang,Gloria V. Echeverria,George Miles,Mothaffar F. Rimawi,Steven A. Carr,Foluso O. Ademuyiwa,Shankha Satpathy,Matthew J. Ellis

DOI: https://doi.org/10.1158/2159-8290.22541898

2023-01-01

Abstract:Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Weiping Peng,Xi Jin,Xiao‐En Xu,Yingju Yang,Ding Ma,Zhi‐Ming Shao,Yi‐Zhou Jiang

DOI: https://doi.org/10.1158/0008-5472.22732543

2023-01-01

Abstract:Supplementary methods, figures, figure legends, and tables
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Yuncheng Bei,Jian He,Xuhui Dong,Yuxin Wang,Sijie Wang,Wan Guo,Chengjie Cai,Zhiye Xu,Jia Wei,Ju Yang,Nan Zhang,Pingping Shen

DOI: https://doi.org/10.1158/0008-5472.23684031.v1

2023-01-01

Abstract:Supplementary Figures and legends
Supplementary Figure 5 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Sreedhar Reddy Suthe,Hang-Ping Yao,Tian-Hao Weng,Chen-Yu Hu,Liang Feng,Zhi-Gang Wu,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22505493

2023-01-01

Abstract:Fig. S5 is about the effect of Zt/g4-MMAE on tumor weight and number.
Supplementary Figure 2 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Sreedhar Reddy Suthe,Hang-Ping Yao,Tian-Hao Weng,Chen-Yu Hu,Liang Feng,Zhi-Gang Wu,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22505502.v1

2023-01-01

Abstract:Fig. S2 is about the cytotoxic effect of Zt/g4-MMAE on a panel of TNBC cell lines
Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Longchuan Bai,Bing Zhou,Chao-Yie Yang,Jiao Ji,Donna McEachern,Sally Przybranowski,Hui Jiang,Jiantao Hu,Fuming Xu,Yujun Zhao,Liu Liu,Ester Fernandez-Salas,Jing Xu,Yali Dou,Bo Wen,Duxin Sun,Jennifer Meagher,Jeanne Stuckey,Daniel F. Hayes,Shunqiang Li,Matthew J. Ellis,Shaomeng Wang

DOI: https://doi.org/10.1158/0008-5472.22416462

2023-01-01

Abstract:<p>This file includes all supporting figures from SI Fig.1 to SI Fig. 23.</p>
Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke‐Da Yu,Rui Zhu,Mei Zhan,Angel Rodriguez,Wei Yang,Stephen T.C. Wong,Andreas Makris,Brian D. Lehmann,Xi Chen,Ingrid A. Mayer,Jennifer A. Pietenpol,Zhi‐Ming Shao,W. Fraser Symmans,Jenny Chang‐Claude

DOI: https://doi.org/10.1158/1078-0432.22446909

2023-01-01

Abstract:Supplementary Figure A1 PDF file 73K, Subgroup analysis of the extended validation cohort
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951168

2024-01-01

Abstract:Supplementary Figure S7. Basic flow chart of PD-1/CD28-CD19 CAR-PD-1+ T cell therapy.
Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

Yan Liu,Yehui Zhou,Kuo‐Hsiang Huang,Xujie Fang,Ying Li,Feifei Wang,Li An,Qingfei Chen,Yunchao Zhang,Aihua Shi,Shuang Yu,Jingzhong Zhang

DOI: https://doi.org/10.1111/cpr.12858

IF: 8.755

2020-06-27

Cell Proliferation

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objectives</h3><p>Traditional cancer therapy and regular immunotherapy are ineffective for treating triple‐negative breast cancer (TNBC) patients. Recently, chimeric antigen receptor‐engineered natural killer cells (CAR NK) have been applied to target several hormone receptors on different cancer cells to improve the efficacy of immunotherapy. Furthermore, epidermal growth factor receptor (EGFR) is a potential therapeutic target for TNBC. Here, we demonstrated that EGFR‐specific CAR NK cells (EGFR‐CAR NK cells) could be potentially used to treat patients with TNBC exhibiting enhanced EGFR expression.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and methods</h3><p>We investigated the cytotoxic effects of EGFR‐CAR NK cells against TNBC cells in vitro and in vivo. The two types of EGFR‐CAR NK cells were generated by transducing lentiviral vectors containing DNA sequences encoding the single‐chain variable fragment (scFv) regions of the two anti‐EGFR antibodies. The cytotoxic and anti‐tumor effects of the two cell types were examined by performing cytokine release and cytotoxicity assays in vitro, and tumor growth assays in breast cancer cell line‐derived xenograft (CLDX) and patient‐derived xenograft (PDX) mouse models.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Both EGFR‐CAR NK cell types were activated by TNBC cells exhibiting upregulated EGFR expression and specifically triggered the lysis of the TNBC cells in vitro. Furthermore, the two EGFR‐CAR NK cell types inhibited CLDX and PDX tumors in mice.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>This study suggested that treatment with EGFR‐CAR NK cells could be a promising strategy for TNBC patients.</p></section>

cell biology
Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73<sup>+</sup> Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Guoming Hu,Pu Cheng,Jun Pan,Shimin Wang,Qingqing Ding,Jing Zhou,Cheng Liu,Xuan Shao,Liming Huang,Jikun Huang

DOI: https://doi.org/10.1158/2326-6066.22542160.v1

2023-01-01

Abstract:Supplemental Figures 1-12 and Supplementary Tables 1-3
Supplementary Figures S1-S2 from Integrin α<sub>v</sub>β<sub>3</sub>-Targeted Radioimmunotherapy of Glioblastoma Multiforme

Anand Veeravagu,Zhaofei Liu,Gang Niu,Kai Chen,Bing Jia,Weibo Cai,Cunjing Jin,Andrew R. Hsu,Andrew J. Connolly,Victor Tse,Fan Wang,Xiaoyuan Chen

DOI: https://doi.org/10.1158/1078-0432.22439677.v1

2023-01-01

Abstract:Supplementary Figures S1-S2 from Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Wen‐Jia Zuo,Yi‐Zhou Jiang,Yujie Wang,Xiao‐En Xu,Xin Hu,Guangyu Li,Jiong Wu,Gen-Hong Di,Ke‐Da Yu,Zhi‐Ming Shao

DOI: https://doi.org/10.1158/1078-0432.22467669

2023-01-01

Abstract:Supplementary Figure S1. Flowchart of study design. Supplementary Figure S2. Protein structure visualizations of the HER2 somatic mutations. Supplementary Figure S3. HER2 mutations L768S and V773L induce HER2 internalization. Supplementary Figure S4. Kaplan-Meier estimates of relapse-free survival (RFS) according to HER2 mutation in different regions.

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Figure 5 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Supplementary Figure 2 from RON Receptor Tyrosine Kinase As a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE

Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor

Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73&lt;sup&gt;+&lt;/sup&gt; Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Supplementary Figures S1-S2 from Integrin α<sub>v</sub>β<sub>3</sub>-Targeted Radioimmunotherapy of Glioblastoma Multiforme

Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73<sup>+</sup> Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer